Channel Therapeutics Corporation news covers the completed transition of the CHRO issuer into Pelthos Therapeutics, a biopharmaceutical company commercializing ZELSUVMI (berdazimer) topical gel for molluscum contagiosum. Coverage also includes Channel's historical clinical-stage biotechnology work on non-opioid, non-addictive pain therapeutics targeting the sodium ion channel NaV1.7.
Recurring developments include ZELSUVMI commercialization, FDA-approved product positioning, NaV1.7 preclinical program updates for chronic pain, acute and chronic eye pain and post-surgical nerve blocks, corporate name and domicile changes, shareholder voting matters, capital-structure disclosures and exchange-listing compliance announcements.
Summary not available.
Summary not available.